Skip to content

A randomized, controlled, double-blind parallel group trial to study the effects of an infant formula containing partially hydrolysed proteins on growth and tolerance in healthy term infants

A randomized, controlled, double-blind parallel group trial to study the effects of an infant formula containing partially hydrolysed proteins on growth and tolerance in healthy term infants

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON27338
Enrollment
276
Registered
2021-06-11
Start date
2021-07-31
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

growth, weight gain, anthropometry, gastrointestinal comfort, safety, suitability, hydrolysate, intact protein, infant formula

Interventions

Sponsors

FrieslandCampina
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: • Full-term infants (born at gestational age =37 weeks). • Healthy birthweight (according to WHO Child Growth Standards): between 2500 and 4200 g, retrieved from medical records • Boys and girls • Apparently healthy at birth and screening • Weight-for-age Z-score (WAZ), weight-for-length (WHZ), and length-for-age (LAZ) Z-scores at screening within the normal range according to WHO Child Growth Standards (i.e. -2 = WAZ,WHZ,LAZ = 2) • Age at enrolment: =28 days of age • Exclusively formula fed for at least 5 days prior to inclusion • Exclusively formula fed during the entire intervention period • Parents agreeing to initiate complementary feeding after finalization of the study • Being available for follow up until the age of approximately 3.5 months • Written informed consent from parent(s) and/or legal guardian(s) aged =18 years

Exclusion criteria

Exclusion criteria: • Gestational age 4200 g • Age at enrolment: >28 days • Severe acquired or congenital diseases, mental or physical disorders, including cow’s milk protein allergy, lactose intolerance and diagnosed medical conditions that are known to affect growth (i.e. GI disorders) • Illness at screening/inclusion • Incapability of parents to comply with the study protocol • Illiterate parents (i.e. not able to read and write in local language) • Participation in another clinical trial • Unwillingness to accept the formula supplied by the study as the only formula for their child during study participation • infants fed a special diet other than standard, non-hydrolysed, cow’s or goat’s milk based infant formula

Design outcomes

Primary

MeasureTime frame
Growth, measured as weight gain in g/day

Secondary

MeasureTime frame
Anthropometry, including - Weight (kg) - Recumbent length (cm and cm/day) - Head circumference (cm and cm/day) - BMI - Z-scores for all the above

Contacts

Public ContactJeske Hageman

FrieslandCampina

jeske.hageman@frieslandcampina.com0611864759

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)